These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36652890)

  • 1. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
    van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
    Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy.
    van Eijck CWF; Sabroso-Lasa S; Strijk GJ; Mustafa DAM; Fellah A; Koerkamp BG; Malats N; van Eijck CHJ
    Neoplasia; 2024 Mar; 49():100975. PubMed ID: 38335839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort.
    Lansbergen MF; Dings MPG; Manoukian P; Fariña A; Waasdorp C; Hooijer GKJ; Verheij J; Koster J; Zwijnenburg DA; Wilmink JW; Medema JP; Dijk F; van Laarhoven HWM; Bijlsma MF
    Transl Res; 2024 Nov; 273():137-147. PubMed ID: 39154856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
    Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Court CM; Janssen QP; Tao AJ; D'Angelica MI; Drebin JA; Gonen M; O'Reilly EM; Jarnagin WR; Wei AC;
    J Am Coll Surg; 2022 Aug; 235(2):342-349. PubMed ID: 35839413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
    Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Ben Abdelghani M; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf DJ; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
    Ann Oncol; 2024 Sep; 35(9):780-791. PubMed ID: 38906254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
    Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
    Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
    van der Sijde F; Dik WA; Mustafa DAM; Vietsch EE; Besselink MG; Debets R; Koerkamp BG; Haberkorn BCM; Homs MYV; Janssen QP; Luelmo SAC; Mekenkamp LJM; Oostvogels AAM; Smits-Te Nijenhuis MAW; Wilmink JW; van Eijck CHJ;
    Front Immunol; 2022; 13():898498. PubMed ID: 36091056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX
    Begg SKS; Birnbaum DJ; Clark JW; Mino-Kenudson M; Wellner UF; Schilling O; Lillemoe KD; Warshaw AL; Castillo CF; Liss AS
    Anticancer Res; 2020 Jul; 40(7):3659-3667. PubMed ID: 32620605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
    O'Leary BR; Ruppenkamp EK; Steers GJ; Du J; Carroll RS; Wagner BA; Buettner GR; Cullen JJ
    Pancreas; 2022 Jul; 51(6):684-693. PubMed ID: 36099493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response in
    Campoverde LE; Batalini F; Bulushi Y; Bullock A
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
    Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
    Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.